CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Self Supportive Care (SSC) AloneWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1641 Normal (9%) Saline Wiki 1.00
drug2122 SAB-301 Wiki 1.00
drug1294 KB109 + Self Supportive Care (SSC) Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19

This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of health in outpatients with mild-to-moderate COVID-19.

NCT04414124 Mild-to-moderate COVID-19 Other: KB109 + Self Supportive Care (SSC) Other: Self Supportive Care (SSC) Alone

Primary Outcomes

Measure: Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)

Time: Day 1 to Day 35

Secondary Outcomes

Description: The composite COVID-19 symptom score is the sum of the 8 cardinal COVID-19 related symptom scores (cough, chills/repeated shaking with chills, muscle pain, fever, headache, anosmia/ageusia, shortness of breath, and sore throat). Each COVID-19 symptom will be recorded by patients on a scale of 0: Absent, 1: Mild: Moderately severe. The overall composite score ranges from 0 (no symptoms) to 24 (very severe)

Measure: Change from baseline to end of intake in overall composite COVID-19 symptom score

Time: Day 1 to Day 14

Description: Resolution of fever is defined as from Day 1 until the day at which a patient's daily maximum temperature achieves and remains below 100.4 Degrees Fahrenheit for the rest of the intake period and for the follow-up period without an antipyretic medication.

Measure: Time to resolution of fever

Time: Day 1 to Day 35

Measure: Proportion of patients with decreased oxygen saturation

Time: Day 14, Day 35

Description: Effect of COVID-19 symptoms on physical activities rated as: not at all, very little, somewhat, quite a lot, could not do physical activities.

Measure: Effect of COVID-19 symptoms on physical activities

Time: Day 1 to Day 35

Measure: Proportion of patients requiring hospitalization

Time: Day 1 to Day 35


No related HPO nodes (Using clinical trials)